Try GOLD - Free
The Drugs Are Working
Bloomberg Businessweek
|January 10, 2022
The first step toward fulfilling a New Year’s resolution just might be a class of prescription weight loss pills and shots. The next steps: Getting patients and doctors to trust them and insurers to cover them

Obesity is a disease. The American Medical Association said so almost a decade ago, and experts convened by the National Institutes of Health did the same when Bill Clinton was president. But it bears repeating, because the conventional wisdom still holds that obesity is a choice. From paleo to Pilates, get-fit-quick schemes revolve around willpower and the assumption that weight loss is entirely a function of diet and exercise. Successful weight loss is partly a function of behavior, yes, but research suggests that genetics and environmental factors can make it extremely difficult or even impossible for some people without outside help. Today, outside help often means surgery, but there’s a much less invasive option quietly sitting on the shelf.
That would be prescription drugs, especially a group of drugs known as GLP-1 receptor agonists, or GLP-1s. These compounds were designed for people with diabetes but have also been shown to cause patients to shed pounds. They simulate a hormone known as glucagon-like peptide 1, the chemical that helps people feel full after they eat. Many people taking a newer GLP-1 drug for weight loss known as Saxenda, for example, lose at least 5% of their body weight, according to one study by the manufacturer. Older generic medications can cost patients as little as $15 a month, while new, brand-name GLP-1s run about $1,400 for a month’s supply of weekly injections.
This story is from the January 10, 2022 edition of Bloomberg Businessweek.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 9,500+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Bloomberg Businessweek

Bloomberg Businessweek US
Instagram's Founders Say It's Time for a New Social App
The rise of AI and the fall of Twitter could create opportunities for upstarts
4 mins
March 13, 2023

Bloomberg Businessweek US
Running in Circles
A subscription running shoe program aims to fight footwear waste
3 mins
March 20 - 27, 2023

Bloomberg Businessweek US
What I Learned Working at a Hawaiien Mega-Resort
Nine wild secrets from the staff at Turtle Bay, who have to manage everyone from haughty honeymooners to go-go-dancing golfers.
10 mins
March 20 - 27, 2023

Bloomberg Businessweek US
How Noma Will Blossom In Kyoto
The best restaurant in the world just began its second pop-up in Japan. Here's what's cooking
3 mins
March 20 - 27, 2023

Bloomberg Businessweek US
The Last-Mover Problem
A startup called Sennder is trying to bring an extremely tech-resistant industry into the age of apps
11 mins
March 20 - 27, 2023

Bloomberg Businessweek US
Tick Tock, TikTok
The US thinks the Chinese-owned social media app is a major national security risk. TikTok is running out of ways to avoid a ban
12 mins
March 20 - 27, 2023

Bloomberg Businessweek US
Cleaner Clothing Dye, Made From Bacteria
A UK company produces colors with less water than conventional methods and no toxic chemicals
3 mins
March 20 - 27, 2023

Bloomberg Businessweek US
Pumping Heat in Hamburg
The German port city plans to store hot water underground and bring it up to heat homes in the winter
3 mins
March 20 - 27, 2023

Bloomberg Businessweek US
Sustainability: Calamari's Climate Edge
Squid's ability to flourish in warmer waters makes it fitting for a diet for the changing environment
4 mins
March 20 - 27, 2023

Bloomberg Businessweek US
New Money, New Problems
In Naples, an influx of wealthy is displacing out-of-towners lower-income workers
4 mins
March 20 - 27, 2023
Translate
Change font size